Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $25
Evolus (EOLS) Receives a Buy From Mizuho Securities
BTIG Initiates Evolus(EOLS.US) With Buy Rating, Announces Target Price $21
Evolus Analyst Ratings
BTIG Initiates Coverage On Evolus With Buy Rating, Announces Price Target of $21
H.C. Wainwright Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $27
Evolus Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Needham Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $22
Evolus Analyst Ratings
Needham Reiterates Buy on Evolus, Maintains $22 Price Target
Optimistic Outlook for Evolus: Buy Rating Backed by Strategic Positioning and Strong Product Performance
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $25
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $22 to $27
Evolus Price Target Raised to $25.00/Share From $22.00 by Barclays
Evolus Is Maintained at Overweight by Barclays
Stifel Nicolaus Reaffirms Their Buy Rating on Evolus (EOLS)
Evolus Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Evolus Analyst Ratings
Needham Reiterates Buy on Evolus, Maintains $22 Price Target
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE) and Evolus (EOLS)